Dr. Nasr - President, Founder & Medical Director, siParadigm diagnostic informatics, LLC - is a nationally recognized Hematopathologist and thought leader in high-complexity Oncology Diagnostics. His expertise in the area has made him a sought-after advisor around innovation, corporate strategy and development, and leadership in pathology and laboratory medicine.
Prior to founding siParadigm, he was the Medical Director of Quest Diagnostics (Teterboro, NJ) and Director of Specialty and Clinical Laboratories at St. Joseph’s Regional Medical Center (Paterson, NJ).
In the face of rapid technology advances, laboratory companies routinely fall short of delivering on physicians' expectations and need for personalized diagnostics. siParadigm was created by practicing pathologists to address this gap in the market by restoring a paradigm of laboratory service and integrity.
The founding vision of Dr. Sherif Nasr has been to grow and adapt to consistently meet the needs of patients, physicians, and healthcare providers with a focus on improving quality of care by providing diagnostic results with the highest quality and unmatched turn-around time (TAT).
siParadigm has earned national accreditation by both CLIA and CAP, in addition to receiving local licensing in several states. To better meet client needs, siParadigm first expanded outside the US mainland to provide services in Puerto Rico, and eventually extended operations internationally to serve a growing client base in Colombia and Egypt.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists). We also hold required licensure in the states as listed below.
Neovare™ is dedicated to providing patients and healthcare professionals with reliable, high quality and affordable hereditary cancer testing solutions. This is backed by siParadigm’s proven know-how and 17 years of clinical oncology expertise through service, integrity and innovation.
The NEOVARE™ Hereditary Cancer Test is easy and simple blood or saliva test that assesses the risk of developing cancer due to hereditary gene mutations and could be covered by your insurance if you meet the criteria of the National Comprehensive Cancer Network (National medical society guidelines).
Top-quality clinical testing is our priority and we use the latest technologies coupled with the most convenient billing method for you. We offer two tests to effectively asses your risk of developing hereditary cancer:
NEOVARE™ DIAGNOSTIC – This test is for patients who have a strong personal or family history of being a carrier of a hereditary cancer mutation. These patients meet the national medical society guidelines and in most cases are covered by their insurance provider. Since these patients are at high risk, we combine two different technologies (NGS and Microarray) for a comprehensive diagnostic panel.
NEOVARE™ SCREEN - This test is for patients who do not meet the national medical society guideline and therefore are not covered by insurance. This, however, does not mean they have zero risk of developing hereditary cancer. It only means that they are not at a higher risk than the average population. Since the national medical society guidelines don't cover all types of hereditary cancers, we offer our patients this test using Microarray Technology. The test is considered a screening test as it utilizes this technology to asses the 24,000 most common hereditary cancer mutations.
As evidence-based personalized medicine displaces empiric approaches to the treatment and management of many cancers, whether, through targeted therapeutics or onco-immunologics, next-generation sequencing is critical to unlocking the power of the patient personal genome and delivering more, and better, insights into disease.
The value of this highly sensitive and rapid technology is evident in disease diagnosis and risk stratification, detection of minimal residual disease (MRD), detection of response or resistance to therapy, and detection of disease re-emergence and disease evolution.
Detection of cytogenetic anomalies by traditional G-banding/chromosome analysis or fluorescent in situ hybridization (FISH) can provide diagnostic and prognostic information and risk stratification for better patient management and even treatment decisions and response.
With the possible exception of advanced molecular techniques, only flow cytometry can provide the wealth of phenotypic information required for the diagnosis of the most complex hematopoietic malignancies and disorders. siParadigm's ten-color flow interrogation reduces specimen requirements and cost, all while delivering exceptionally efficient turnaround times.
Our hematopathologists are expert morphologists; a thorough understanding of the subtleties of cell architecture and pattern recognition means our integrated reporting is rooted in classic techniques married with state-of-the-art equipment and an extensive suite of immunohistochemical and special stains.
Taken on their own, results from individual technologies can survey a number of disease attributes, but a complete patient picture or dossier is dependent on expert selection of medically-appropriate technologies and a clinicopathologic correlation that gives information to diagnose, stratify, and treat in one place.